2026 POSTER PRESENTATIONS
Preliminary List as of March 27, 2026 - Check back for more!
2BIND
THE FORMAT MATTERS: STABILITIES OF BISPECIFICS
2BIND
BINDING KINETICS MEASURED ON CELLS – PAIN OR GAIN?
A-ALPHA BIO
BEYOND THE PDB: THE SYNTHETIC EPITOPE ATLAS FOR TRAINING ANTIBODY DESIGN MODELS
AAX BIOTECH AB
OPTI-MAB®: A NOVEL SCFV FORMAT FOR IMPROVED THERAPIES
ABBVIE, INC.
AUTOMATED IMMUNOPEPTIDOMICS: HIGH-THROUGHPUT MHC PEPTIDE PROFILING ON THE ASSAYMAP BRAVO PLATFORM
ABTERRA BIOSCIENCES, INC.
GRIFFIN: A MASS SPECTROMETRY-BASED METHOD FOR POLYCLONAL ANTIBODY SEQUENCING DIRECTLY FROM PROTEIN
ABTERRA BIOSCIENCES, INC.
VHH DISCOVERY BEYOND B CELLS - ANTIBODY DISCOVERY FROM SERUM USING MACHINE LEARNING MODELS FOR IN SILICO SELECTION
ACADEMIA SINICA
MULTIOMIC PROFILING OF CAR-T CELLS IDENTIFIES DRIVERS OF LONG-TERM PERSISTENCE
ADIMAB LLC
HARNESSING THE ADIMAB PLATFORM FOR THE DISCOVERY OF TTX-080: A CLINICAL HLA-G ANTIBODY
ADIMAB LLC
SPECIFICITY OF RARE HIGH-AFFINITY HUMAN TCRS DERIVED FROM SYNTHETIC YEAST-BASED LIBRARIES
ADIMAB LLC
ANTI-CD3 HEAVY CHAIN-ONLY ANTIBODY (HCAB) PANEL FOR USE IN T-CELL ENGAGING THERAPEUTICS
AGILENT TECHNOLOGIES
ACCURATE MAB SIZING BY CE-SDS USING THE NIST MAB AS A LADDER FOR THE AGILENT PROTEOANALYZER SYSTEM
AJINOMOTO CO., INC.
CORYNEX®: SCALABLE SECRETION SERVICE FOR LONG-CHAIN PEPTIDES INCLUDING GLP-1-RELATED PEPTIDES
AJINOMOTO CO., INC.
CORYNEX® FOR NEXT-GENERATION VHHS: SITE-SPECIFIC CONJUGATION VIA NCAA INCORPORATION AND HALF-LIFE EXTENSION VIA PASYLATION®
ALBERT EINSTEIN COLLEGE OF MEDICINE
ACCURATE AFFINITY MODELS FOR SH2 DOMAINS FROM PEPTIDE BINDING ASSAYS, FREE-ENERGY REGRESSION AND IMPORTANCE OF LIBRARY STRUCTURE
ALBERT EINSTEIN COLLEGE OF MEDICINE
DEVELOPMENT OF INNATE IMMUNE CELL REDIRECTORS FOR THE DEPLETION OF ANTIGEN SPECIFIC AUTOREACTIVE T CELLS
ANKYRA THERAPEUTICS
ANCHORED FULLY HUMANIZED MONOCLONAL ANTIBODIES FOR CANCER TREATMENT
ARDIGEN
AI-DRIVEN DE NOVO GENERATION OF PROTEIN BINDERS
ARDIGEN
ARDITOX: SAFER PHLA-TARGETED IMMUNOTHERAPIES THROUGH AI AND COMPUTATIONAL IMMUNOLOGY
ARGENX BVBA
IMMUNOLOGY INNOVATION PROGRAM: DEVELOPING ANTIBODIES AGAINST NOVEL TARGETS VIA CO-CREATION
ASTRAZENECA
FROM MONTHS TO WEEKS: OPTOFLUIDIC PLATFORM POWERS RAPID ANTIBODY IDENTIFICATION ACROSS INDICATIONS
AUREKA BIOTECHNOLOGIES
ACTRIIA/ACTRIIB DUAL ANTAGONIST MAB DRIVES WEIGHT LOSS WHILE PRESERVING LEAN MUSCLE
BASELAYER BIOSCIENCES
STRUCTURAL CLARITY FOR BIOLOGICS: HIGH-RESOLUTION PROTEIN CHARACTERIZATION SERVICES FROM BASELAYER BIOSCIENCES
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO.
CRB2104: A 2:1 AMHR2/CD3 T CELL ENGAGER TARGETING AMHR2-POSITIVE SOLID TUMORS
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO.
BCG015: A FIRST-IN-CLASS ANTIBODY-DRUG CONJUGATE TARGETING TM4SF5 FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO.
NOVEL BLOOD-BRAIN BARRIER PENETRATING HEAVY CHAIN-ONLY ANTIBODIES TARGETING CD98
BIOINTRON
ABDROP™ SPEEDS: ACCELERATING YOUR ANTIBODY DISCOVERY WITH SINGLE B SOLUTION
BIOINTRON
SPEED COUNTS WHILE QUALITY MATTERS: A FAST-TRACK APPROACH TO BISPECIFIC ANTIBODY PRODUCTION
BIOINTRON
DATA-DRIVEN DEVELOPABILITY ASSESSMENT OF ANTIBODY CANDIDATES USING HIGH-THROUGHPUT BIOPHYSICAL ASSAYS
BIO-TECHNE
HIGH-THROUGHPUT ANTIBODY PRODUCTION COUPLED WITH RAPID CHARGE AND SIZE CHARACTERIZATION BY ICIEF AND CE-SDS
BOEHRINGER INGELHEIM
CHALLENGES AND OPPORTUNITIES IN TARGETING PEPTIDE-HLAS WITH ANTIBODY THERAPEUTICS FOR ONCOLOGY
BOKU VIENNA
ENGINEERING A SMALL MOLECULE–CONTROLLED SWITCH FOR CAR T CELL REGULATION
BOKU VIENNA
MINICARBIDS- A NOVEL ENGINEERING PLATFORM FOR SMALL, HUMAN-DERIVED BINDING DOMAINS TAILORED FOR CAR T CELL THERAPY
BOKU VIENNA
ENGINEERING CAR T CELLS TO SPECIFICALLY TARGET LIGAND-ACTIVATED EGFR
BPS BIOSCIENCE, INC.
ADVANCED TOOLS FOR BISPECIFIC ANTIBODY GENERATION AND VALIDATION
BROAD INSTITUTE
RABIT: RAPID AUTOMATED BINDER IDENTIFICATION TECHNOLOGY
BROAD INSTITUTE
EVOLUTION OF BOTULINUM NEUROTOXIN PROTEASES TO INDUCE INFLAMMATORY CELL DEATH IN CANCER CELLS
BRUKER CELLULAR ANALYSIS
FUNCTION-FIRST SINGLE-CELL DISCOVERY AND CHARACTERIZATION OF BISPECIFIC T CELL ENGAGERS
CELLPLUS BIOTECHNOLOGY (SUZHOU) LTD.
HIGH-TITER (>1.8 G/L) AND COST-EFFICIENT TRANSIENT EXPRESSION IN CHO-K1 CELLS: ENABLED BY AN OPTIMIZED PLUG-AND-PLAY SYSTEM AND PEL-BASED APPROACH
CHARLES RIVER LABORATORIES
NEW APPROACH METHODOLOGIES (NAMS): RETROGENIX® TECHNOLOGY FOR RAPID EARLY-STAGE HIGH-THROUGHPUT SCREENING AND TOXICOLOGY SPECIES SELECTION
CHEMICAL COMPUTING GROUP
3DPREDICT/AB - HIGH THROUGHPUT ANTIBODY STRUCTURE AND ENSEMBLE PROTEIN PROPERTY PREDICTIONS
CHEMICAL COMPUTING GROUP
PHARMACOPHORE-GUIDED VIRTUAL SCREENING OF ANTIBODY FORMATS
CHINESE UNIVERSITY OF HONG KONG
PREDICTION OF IMMUNOGENICITY AND VACCINE EFFECTIVENESS USING VIRAL GENOMIC VARIATION
CODING BIO
A FUNCTION-FIRST ML-GUIDED HIGH THROUGHPUT SCREENING PLATFORM FOR THE DISCOVERY OF VHH-BASED T-CELL ENGAGERS
COLUMBIA UNIVERSITY
ENGINEERING IMMUNE RESPONSES WITH DENDRITIC CELL-TARGETING NANOBODIES
CONIGEN BIOSCIENCE
NOVEL SOLUBLE FC-FREE CD19 DIMERIC PROTEIN FOR SPECIFIC, SENSITIVE AND BROADLY APPLICABLE CD19 CAR-T CELL DETECTION BY FLOW CYTOMETRY
CONIGEN BIOSCIENCE
A PANEL OF CLASS A, B AND F GPCR-SPECIFIC ANTIBODIES CAN DETECT THE TARGETS EXPRESSED ON LIVE CELL SURFACES BY FLOW CYTOMETRY
CONIGEN BIOSCIENCE
MULTI-PASS COMPLEX PROTEINS DISPLAYED ON VIRUS-LIKE PARTICLES ARE BIOACTIVE IN BINDING TO SPECIFIC ANTIBODIES AND LIGANDS
DEVELOPMENT CENTER FOR BIOTECHNOLOGY
LYSWARD™ : AN ENGINEERING PLATFORM TO GENERATE A PH-DEPENDENT ANTIBODY FOR ANTIBODY DRUG CONJUGATE
DIFFUSE BIO, INC.
RAMAX: A PLATFORM FOR ULTRA-RAPID BINDER SCREENING, DISCOVERY, AND OPTIMIZATION
DOTMATICS
ANTIBODY & THERAPEUTICS DISCOVERY: INTERROGATING LARGE NGS DATASETS
EVOLVEIMMUNE THERAPEUTICS
ENGINEERING EVOLVE-101: A CD180 TARGETING T CELL ENGAGER WITH INTEGRATED CD2 CO-STIMULATION
FAPON BIOPHARMA
FPE024,A CD19/BCMA DUAL-TARGETING VHH FORMAT T-CELL ENGAGER WITH NOVEL CD3 BINDER FOR ENHANCED POTENCY AND SAFETY PROFILE
FUSION ANTIBODIES PLC
OPTIMAL®: MAMMALIAN DISPLAY FOR ANTIBODY DISCOVERY
FUSION ANTIBODIES PLC
A RATIONAL AFFINITY MATURATION PLATFORM - RAMP
GATOR BIO
AI-ENGINEERED NOVOBODY™-BASED PROBE FOR “HIGH CAPACITY, LOW DRIFT” BLI ANALYSIS OF HIS-TAGGED PROTEINS
GENENTECH
ESTABLISHING RELIABLE PK EVALUATION CRITERIA: A VALIDATED TRANSCYTOSIS ASSAY FOR MONOCLONAL ANTIBODIES AND COMPARATIVE STUDY WITH SCID PK
GENESCIENCE PHARMACEUTICAL CO., LTD.
GENSCI155, A NOVEL LONG-ACTING IGF-1 PEPTIDE ANALOG FOR THE TREATMENT OF SPIGFD, BPD AND AIS DISEASES
GENSCRIPT
A NEXT-GENERATION TRANSIENT CHO EXPRESSION PLATFORM ACCELERATING ANTIBODY DISCOVERY FROM SCREENING SERVICE TO IN-HOUSE PRODUCTION
GENSCRIPT
ACCELERATING AI-DRIVEN DISCOVERY WITH AN INTEGRATED CELL-FREE SEQUENCE-TO-DATA PLATFORM
GENSCRIPT
IMPROVING SCALABLE, HIGH-THROUGHPUT AFFINITY PROTEIN PURIFICATION WORKFLOWS WITH MAGNETIC BEADS-BASED AUTOMATED SOLUTIONS
GSK
ENHANCING SOLUBILITY AND EXPRESSION OF A BINDER THROUGH TARGETED LINKER ENGINEERING
HARVARD UNIV
PRECISION BRAIN SHUTTLE PLATFORM TAILORED TO BREAST CANCER BRAIN METASTASIS
HONGCHENG BIOPHARMA
DISCOVERY AND CHARACTERIZATION OF A HUMAN AND NHP CROSS-REACTIVE ANTI-CD3 NANOBODY
I3 MEMBRANE CORPORATION
ELECTROCHEMICAL ELUTION REDUCES AGGREGATION OF PH-SENSITIVE MONOCLONAL ANTIBODIES IN DIGITAL MEMBRANE CHROMATOGRAPHY
I3 MEMBRANE CORPORATION
DIGITAL MEMBRANE CHROMATOGRAPHY — A NEW WAY TO RAPID ANTIBODY PURIFICATION FOR TOP-DOWN MASS SPECTROMETRY
ICGEB
DEVELOPMENT OF NOVEL ANTI-MALARIAL ANTIBODY DRUGS AGAINST PLASMODIUM FALCIPARUM
ILLIMIS THERAPEUTICS
ENGINEERING A GAS6 FUSION PROTEIN (GAIA) ENABLING NON-INFLAMMATORY AMYLOID-ß CLEARANCE FOR SAFER ALZHEIMER’S DISEASE THERAPY
IMMATICS BIOTECHNOLOGIES GMBH
UNLOCKING TUMOR ACCESS: TARGETING COL6A3 ON THE STROMA OF SOLID TUMORS WITH A TCR-BASED BISPECIFIC
IMMUTO SCIENTIFIC
MULTIMODAL FUSION OF EMPIRICAL STRUCTURAL DATA AND DEEP LEARNING FOR IMPROVED MODELING OF ANTIBODY–ANTIGEN COMPLEXES
INSTITUT FOR PROTEIN INNOVATION
IPIABDEV:INTERPRETABLE MACHINE LEARNING FOR ANTIBODY DEVELOPABILITY PREDICTION AND DISCOVERY
INTEGRATED DNA TECHNOLOGIES
DIVERSE LIBRARY GENERATION USING IDT OPOOLS AND SYNTHETIC BIOLOGY CUSTOM SOLUTIONS
INVENRA
ENABLING RAPID BISPECIFIC ANTIBODY DISCOVERY WITH INVENRA’S B-BODY PLATFORM
INVENRA
FROM HIGH-QUALITY MAB DISCOVERY TO MULTISPECIFIC THERAPEUTICS: DISCOVERED. DESIGNED. DELIVERED
JASCO, INC.
RAPID AND ROBUST EVALUATION OF HIGHER ORDER STRUCTURAL DIFFERENCES IN BISPECIFIC ANTIBODIES BY CIRCULAR DICHROISM SPECTROSCOPY
JOHNS HOPKINS UNIVERSITY
MECHANISTIC INSIGHTS INTO THE IMMUNOMODULATORY EFFECTS OF A POTENTIATING ANTIBODY TARGETING THE INTERLEUKIN-7 CYTOKINE
JOHNS HOPKINS UNIVERSITY
ENGINEERED CD19-TARGETING INTERLEUKIN-21 MIMETIC TO STUDY AND MANIPULATE B-CELL BIOLOGY
JOHNS HOPKINS UNIVERSITY
ENGINEERING INTERLEUKIN-4-BASED ANTIBODIES FUSION PROTEINS FOR TARGETED IMMUNE MODULATION
JOHNS HOPKINS UNIVERSITY
DESIGN OF A SUSPENSION-BASED MAMMALIAN CELL INTERACTION PLATFORM FOR ANTIBODY DISCOVERY
JOHNS HOPKINS UNIVERSITY
TARGETED ANTIBODY/CYTOKINE FUSION PROTEIN ANTAGONISTS TO OVERCOME TREG-MEDIATED IMMUNOSUPPRESSION IN TUMORS
JOHNS HOPKINS UNIVERSITY
ENGINEERED MULTI-PARATOPIC ANTIBODY-DRUG CONJUGATES TARGET AND DESTROY TUMOR CELLS THROUGH MULTIPLE MODALITIES
KANEKA EUROGENTEC SA BIOLOGICS
GMP VHH PLATFORM FOR RAPID TOX AND CLINICAL ACCESS
KIMIALYS
K-NEURO: AN SPR-BASED PLATFORM FOR ACCELERATING DRUG DISCOVERY IN NEURODEGENERATIVE DISEASES
KITE, A GILEAD CO.
ACCELERATED PRODUCTION OF BIOTINYLATED PROTEIN REAGENTS THROUGH COEXPRESSION WITH BIOTIN LIGASE
KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
PROGRAMMABLE DNA NANOSTRUCTURES FOR SPATIAL ORGANIZATION AND DELIVERY OF GROWTH FACTOR–MIMICKING PEPTIDES
KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
UNLOCKING THERAPEUTIC POTENTIAL: WHY SITE-SPECIFIC HYBRIDIZATION IS ESSENTIAL OVER NON-SPECIFIC PEPTIDE ADSORPTION ON DNA ORIGAMI
KYOTO UNIVERSITY
DEVELOPMENT OF CIS-BINDING BIPARATOPIC ANTIBODIES AS TNFR2 ANTAGONISTS
LUDGER LTD.
COMPREHENSIVE GLYCOSYLATION ANALYSIS TO MEET REGULATORY REQUIREMENTS: FULL N-GLYCAN CHARACTERISATION AND QUANTITATION OF SIALIC ACIDS
MATWINGS TECHNOLOGY
IMPROVING PROTEIN STABILITY THROUGH DEEP LEARNING METHOD: THE AIACCLBIO® PLATFORM
MERCK RESEARCH LABORATORIES
ENABLING HIGH-THROUGHPUT CE-SDS AND PEPTIDE MAPPING THROUGH AUTOMATED CHARACTERIZATION WORKFLOWS ON THE HAMILTON STARLET
METAPHORE
MULTI-SPECIFIC MOLECULE DISCOVERY WITH THE METAPHORE KNOWLEDGE BASE
METAPHORE BIOTECHNOLOGIES
ML-GUIDED DESIGN OF GLP-2R AGONIST ANTIBODIES WITH IMPROVED IN VIVO ACTIVITY SUPPORTING EXTENDED DOSING
MICHIGAN STATE UNIVERSITY
BEYOND THE IMPACT: ANTIBODY SEQUENCES AS PREDICTIVE BIOMARKERS FOR PEDIATRIC TRAUMATIC BRAIN INJURY
MILLIPORESIGMA
RATIONAL DESIGN OF PROTEIN A VARIANTS USING AI-DRIVEN IN SILICO MODELING FOR ENHANCED AFFINITY CHROMATOGRAPHY PERFORMANCE
MILTENYI BIOTEC B.V. & CO. KG
A PROTEOTRANSCRIPTOMIC APPROACH TO GENERATE MONOCLONAL ANTIBODIES BY LC-MS/MS AND SINGLE CELL BCR SEQUENCING
MOLECULE MIND
GENERATION OF A PD-1/IL-2V BISPECIFIC ANTIBODY WITH AI-POWERED MOLECULEOS(MOS) TECHNOLOGY
NATIONAL INSTITUTES OF HEALTH, NATIONAL CANCER INSTITUTE
QUEST FOR MUCIN-4 GLYCOPEPTIDE SPECIFIC ANTIBODIES AS POTENTIAL ANTI-CANCER IMMUNOTHERAPIES
NATIONAL INSTITUTES OF HEALTH, NATIONAL CANCER INSTITUTE
DISCOVERY OF CAMEL VHH AND SHARK VNAR NANOBODIES BY PHAGE DISPLAY FOR DEVELOPING CANCER THERAPEUTICS
NUCLERA
FROM SEQUENCE TO ASSAY-READY GPCRS IN 48 HOURS USING CELL-FREE MULTIPLEX SCREENING
NUCLERA
RAPID RANK-ORDERING OF 96 TRASTUZUMAB VARIANTS USING CELL-FREE RECOMBINANT ANTIBODY SCREENING
OMNIAB
EMPOWERING THE EFFICIENT DISCOVERY OF ULTRALONG CDRH3 ANTIBODIES WITH HIGH-THROUGHPUT XPLORATION® WORKFLOWS
PENTIXAPHARM AG
HARNESSING THE BEST OF BOTH WORLDS: GT-008, A VERSATILE TUMOR-SELECTIVE ANTI-CD24 ANTIBODY FOR RADIOTHERANOSTIC AND ADC STRATEGIES
PHARMARON
MULTI ATTRIBUTE MONITORING AND COMPREHENSIVE ANALYSIS OF MAB CQAS THROUGHOUT THE MANUFACTURING PROCESS
PROANALYTICS
INCREASE ANTIBODY TITERS IN FLASKS WITH AUTOMATED CONTINUOUS FEEDING
PROTEIN METRICS BY DOTMATICS
AUTOMATED, HIGH-THROUGHPUT SCREENING OF COMPLEX BIOLOGICS
PROTEINTECH GERMANY GMBH
FLEXABLE 2.0 – A VERSATILE TOOL TO LABEL ANTIBODIES WITH DYES, ENZYMES OR OLIGOS
PROTEINTECH GERMANY GMBH
VHHS AS TOOLS FOR THE ANALYSIS OF ANTIBODIES AND CYTOKINES USING BLI AND SPR
PROTIFI
MAM-EASY: A STANDARDIZED KIT-BASED WORKFLOW FOR REPRODUCIBLE BIOTHERAPEUTIC QUALITY MONITORING
QUANTUM-SI
SINGLE-MOLECULE PROTEIN SEQUENCING FOR THE CHARACTERIZATION OF PROTEINS, PURIFICATION IMPURITIES, AND BINDING KINETICS
RONDO THERAPEUTICS
DEVELOPABILITY OF RNDO-564: A NOVEL CD28 X NECTIN-4 COSTIMULATORY BSAB FOR THE TREATMENT OF SOLID TUMORS
ROUKENBIO
LOCIN: A TARGETED INTEGRATION SYSTEM FOR THE EFFICIENT CREATION OF ISOGENIC MAMMALIAN CELL LINES
ROUKENBIO
TARGET DENSITY MATTERS - BINDING KINETICS OF ANTIBODY-BASED THERAPEUTICS ARE HIGHLY INFLUENCED BY TARGET EXPRESSION LEVELS
ROUKENBIO
DEVELOPMENT OF A HIGH-THROUGHPUT MULTIMODAL PATIENT-DERIVED PLATFORM INTEGRATING AUTOLOGOUS FIBROBLASTS AND TUMOUR-INFILTRATING LYMPHOCYTES FOR COLORECTAL CANCER DRUG DISCOVERY
ROYAL VETERINARY COLLEGE
CELL LINE GENOME ENGINEERING
SANOFI
TWO CELL LINES, ONE GOAL: ENABLING RELIABLE CELL-BASED ASSAY CRITICAL REAGENT PRODUCTION
SCRIPPS RESEARCH INSTITUTE
STRUCTURAL INSIGHTS INTO IN VIVO ANTIBODY DIVERSIFICATION: HOW CR3022 EVOLVES TO TARGET CONSERVED EPITOPES FOR PAN-SARBECOVIRUS NEUTRALIZATION
SEISMIC THERAPEUTIC
YEAST DISPLAY FOR PROTEASE ENGINEERING AND ACTIVITY SCREENING
SEISMIC THERAPEUTIC
DISCOVERY OF A NOVEL IGM CLEAVING PROTEASE TO TREAT AUTOIMMUNE DISEASES
SEISMIC THERAPEUTIC
IDENTIFICATION AND CHARACTERIZATION OF A FIRST-IN-CLASS IGE ELIMINATING THERAPEUTIC USING MULTI PARAMETER MOLECULAR ASSESSMENT OF AN IGE-SPECIFIC PROTEASE
SELVITA SA
END-TO-END SOLUTIONS FOR PROTEIN BIOLOGICS: FROM TARGET SELECTION TO DRUG DELIVERY
SEOUL NATIONAL UNIVERSITY
STEALTH-BODY: A NEXT-GENERATION IGG FC VARIANT WITH COMPLETE EFFECTOR SILENCING AND PRESERVED DEVELOPABILITY
SEOUL NATIONAL UNIVERSITY
ENGINEERED B7-H6 ENHANCES NKP30-MEDIATED NK CELL ACTIVATION IN BISPECIFIC ENGAGERS
SEOUL NATIONAL UNIVERSITY
PRECISION FC ENGINEERING VIA GLYCOSYLATION-COMPETENT CHO DISPLAY ENABLES SELECTIVE FC?RIIIA TARGETING AND ENHANCED ANTITUMOR ACTIVITY
SLINGSHOT BIOSCIENCES
CELL MIMICS PROVIDE ROBUST CONTROL FOR T CELL MEMORY PHENOTYPING PANELS
STEVENS INSTITUTE OF TECHNOLOGY
DECODING LOCAL INTERACTIONS OF NOVEL EXCIPIENTS WITH ANTIBODIES FOR VISCOSITY PREDICTION IN HIGH-CONCENTRATION MAB FORMULATIONS VIA MOLECULAR DYNAMICS
SUNY BINGHAMTON
LINKER ENGINEERING OF FGFR4-TARGETED EXATECAN ANTIBODY–DRUG CONJUGATES ENABLES POTENT ANTIGEN-DEPENDENT CYTOTOXICITY AND IMPROVED PHARMACOKINETIC PERFORMANCE
SUNY BINGHAMTON
NEXT-GENERATION IMMUNOSUPPRESSIVE ADCS: TARGETED DELIVERY OF GLUCOCORTICOIDS TO ACTIVATED IMMUNE CELLS FOR CHRONIC INFLAMMATION
TAIHO PHARMACEUTICAL CO., LTD.
DESIGN OF BISPECIFIC ANTIBODY FC REGION EMPLOYING A SHARK-HUMAN CHIMERIC AND ASYMMETRIC FORMAT
TAKEDA
OPTIMIZING PLASMID CONSTRUCT WORKFLOW AND DESIGN FOR YIELD AND CLONING EFFICIENCY
TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER
OPTIMIZATION OF MEMBRANE SCAFFOLD PROTEINS (MSPS) FOR LIPID NANODISCS RECONSTITUTION USING A PD-10 TO IMPROVE QUALITY AND YIELD FOR BIOPHYSICAL TECHNIQUES
THERMO FISHER SCIENTIFIC
DE-RISKING ANTIBODY DEVELOPMENT EARLY: COMBINING HIGH-YIELD EXPRESSION WITH DEEP DEVELOPABILITY PROFILING
THERMO FISHER SCIENTIFIC
HIGH-THROUGHPUT MEDIA AND FEED SCREENING
THOMSON INSTRUMENT COMPANY
THOMSON 7L FLASK REPLACING BIOREACTOR AND CELL BAGS BETWEEN 5L TO 6L/FLASK – ABILITY TO GROW UP TO 35L/SHAKER
THOMSON INSTRUMENT COMPANY
COMPARISON OF THOMSON OPTIMUM GROWTH® 7L FLASKS VS AMBR® 250 BIOREACTOR SYSTEMS USING STABLE CHO CELLS
THOMSON INSTRUMENT COMPANY
UNIVERSAL RAPID CLEAR® 24-WELL FILTER PLATE (7ML); A 5-MINUTE SPIN FOR CLARIFICATION SOLUTION FOR ALL MOLECULE TYPES
THOMSON INSTRUMENT COMPANY
21-FOLD INCREASE IN PLASMID PRODUCTION YIELD COMPARED TO TRADITIONAL METHODS
TUFTS UNIVERSITY
DOXORUBICIN-INDUCED FIBROBLAST ACTIVATION AND PRO-INVASIVE CHANGES IN ECM CAN BE SUPPRESSED BY NINTEDANIB
UNIVERSITY COLLEGE LONDON
GLYCOPEPTIDE PHAGE DISPLAY FOR THE DISCOVERY OF NEW TREATMENTS AGAINST PATHOGENIC LECTINS
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
BIPARATOPIC AND TETRAVALENT SIGLEC-10 ANTIBODIES MODULATE IMMUNE CELL REACTIVITY
UNIVERSITY OF LISBON
IN VIVO PHAGE DISPLAY FOR THE DISCOVERY OF FUNCTIONAL TUMOR-TARGETING AND BBB-CROSSING ANTIBODIES
UNIVERSITY OF MICHIGAN
COMPUTATIONAL MODELING OF ANTIBODY-DRUG CONJUGATES (ADCS) FOR HIV TREATMENT
UNIVERSITY OF MICHIGAN
NEUROCYTOKINE SHUTTLES FOR EFFICIENT AND SUSTAINED CNS IMMUNOMODULATION
UNIVERSITY OF MICHIGAN
DUAL-TARGETED OLIGOSHUTTLES MEDIATE EFFICIENT REDUCTION OF NEURONAL GENE EXPRESSION AFTER PERIPHERAL ADMINISTRATION
UNIVERSITY OF MINNESOTA, TWIN CITIES
STRUCNS REVEALS INTERACTION-WEIGHTED NETWORK TOPOLOGY AS THE DRIVING PREDICTOR OF ABSOLUTE STABILITY OF NATURAL AND DE NOVO PROTEINS
UNIVERSITY OF OXFORD
THE MOLECULAR REACH OF ANTIBODIES DETERMINED BY A NOVEL SPR-BASED ASSAY IS INDEPENDENT OF THEIR ISOTYPE
UNIVERSITY OF OXFORD
USING COMBICELLS TO MEASURE ANTIGEN SENSITIVITY OF T CELL ENGAGERS
UNIVERSITY OF PENNSYLVANIA
COMPACT HELICAL BUNDLE SCAFFOLDS AS HIGH-BRIGHTNESS NIR PROBES FOR FLUORESCENCE-GUIDED SURGERY
UNIVERSITY OF PENNSYLVANIA
AUTOANTIBODY-BASED ANTIBODY-DRUG CONJUGATES AS PERSONALIZED CANCER THERAPY
UNIVERSITY OF TEXAS AUSTIN
LEVERAGING THE TUMOR MICROENVIRONMENT FOR CONDITIONAL ANTIBODY-DRUG CONJUGATE ACTIVATION
UNIVERSITY OF UTAH
FUNCTIONAL FLEXIBILITIES AND CONSTRAINTS OF VRC01 LINEAGE HIV BROADLY NEUTRALIZING ANTIBODIES REVEALED BY DEEP MUTATIONAL SCANNING
UNIVERSITY OF UTAH
INTEGRATING MACHINE LEARNING WITH MDS TO IMPROVE PANCACE
UNIVERSITY OF WASHINGTON
DESIGN, STABILIZE, DESIGN: USING A VARIETY OF MACHINE LEARNING TOOLS TO CREATE DE NOVO TLRS AND THEIR ANTIBODIES
UNIVERSITY OF WASHINGTON
IDENTIFICATION AND BIOPHYSICAL CHARACTERIZATION OF A NOVEL DOMAIN-SWAPPED CAMELID ANTIBODY SPECIFIC FOR FENTANYL.
VIVA BIOTECH
BI-SPECIFIC ANTIBODY GENERATION - IN HOUSE STUDY BY CONTROLLED FAB-ARM EXCHANGE (CFAE)
VRG THERAPEUTICS LTD.
AI-MPRO: TACKLING CHALLENGING TARGETS WITH DE NOVO MINIPROTEINS
WASHINGTON UNIVERSITY
HIGH-THROUGHPUT MAPPING OF HEMAGGLUTININ PH STABILITY USING YEAST DISPLAY AND DEEP MUTATIONAL SCANNING
WATCHMAKER GENOMICS
IN SILICO OPTIMISATION OF INHIBITOR PROTEIN WITH IMPROVED THERMOSTABILITY AND EXPRESSION
WATERS CORPORATION
ORTHOGONAL APPROACHES TO AGGREGATION RISK MONITORING AND SCREENING FOR COMPLEX BIOLOGICS
WATERS CORPORATION
COMPREHENSIVE LC-MS ANALYTICAL ASSAYS FOR ANTIBODY-OLIGONUCLEOTIDE CONJUGATE (AOC) AND SIRNA LINKER-PAYLOAD CHARACTERIZATION
WEIZMANN INSTITUTE
COMPUTATIONAL DESIGN OF SYNTHETIC ANTIBODY REPERTOIRES FOR ENHANCED DEVELOPABILITY
WHEELER BIO
LUEDEKING-PIRET REGRESSION FOR MULTI-STEP-AHEAD FORECASTING AND CLONE SELECTION IN MONOCLONAL ANTIBODIES BIOMANUFACTURING
WONKWANG UNIVERSITY
BROAD-REACTIVE MONOCLONAL ANTIBODIES TARGETING INFLUENZA H5NX FOR INTEGRATED PANDEMIC READINESS
WUXI BIOLOGICS
TRANSLATIONAL IN VIVO CHARACTERIZATION PLATFORM FOR T CELL ENGAGERS VIA NHP AND HFCRN MICE
WUXI BIOLOGICS
IN-DEPTH SPR CHARACTERIZATION THROUGHOUT BIOLOGICS DRUG DISCOVERY AND DEVELOPMENT
XTOP BIOTHERAPEUTICS
CROSSBODY: A VARIABLE REGION DOMAIN-SPLITTING MULTISPECIFIC ANTIBODY ARCHITECTURE ENABLING TUMOR-SELECTIVE TARGET ENGAGEMENT FOR PRECISION IMMUNOTHERAPY
YONSEI UNIVERSITY
FLUOROSULFURYL DERIVATIVES OF ESTABLISHED DRUGS FOR IMAGING RADIOPHARMACEUTICALS
YUMAB GMBH
NEXT-GENERATION TCR-LIKE ANTIBODIES WITH IMPROVED SPECIFICITY PROFILES
YUROGEN BIOSYSTEMS LLC
DEVELOPMENT OF A HUMANIZED ANTI-CDH3 ANTIBODY USING A SINGLE-CELL STRATEGY FOR DISEASES WITH ABERRANT CDH3 EXPRESSION